Franck Remoue holds a Ph.D. degree. He is an immunologist of infectious disease and a Researcher of the Institute of Research for Development (IRD) with large experience (19 years) in the immunoepidemiology of parasitic diseases, such as schistosomiasis and malaria. He has particularly worked in Africa (from 1994 in Senegal, in Benin during 4 years, and other collaborative projects in Mali, Burkina-Faso, Angola, Cameroon, Reunion Island, and Ivory Coast) closely associating its researches from the field to the laboratory (installation and development of immunological technologies). Since 2002, he has initiated and has been the Head of EPIVECT (Epidemiology of Vectors) program (10 persons) which is the worldwide leader program of the study of human antibody response to vector saliva. One major goal is especially to develop an immunoepidemiological biomarker of human exposure to mosquito bites and its applications in vector control and measure the risks of malaria and arbovirus emergent diseases. For 5 years, this team performed several expertise and consultancies of the technology and scientific transfers of this salivary biomarker (mosquito, Glossina, leishmaniasis vectors, etc.) in Africa (MRTC in Mali, Senegal, Angola, Ivory Cost, Kenya, Uganda, Burkina-Faso, Cameroon), islands of Indian Ocean and Pacific, and in Europe (France, Italy). In addition, this team works on the immunological man-vector relationships to evaluate the influence of saliva exposure to the acquired immune response to malaria antigens and its consequences on the malaria transmission. Since October 2009, he has been affected in MIVEGEC Unit to focus this work on (i) salivary biomarker to its application of malaria vector control (development of multidisciplinary tool box of efficacy/effectiveness of vector control) and to Aedes-borne diseases risks (Dengue, Chikungunya) and Aedes vector control and (ii) immunomodulatory effect of mosquito exposure (i.e., saliva) on antipathogen immunity and transmission.
Biography Updated on 4 April 2012